Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This phase Ib trial tests the safety and effectiveness of tafasitamab, acalabrutinib, and
obinutuzumab in treating patients with previously untreated chronic lymphocytic leukemia
(CLL). CLL is a type of cancer that develops from a specific white blood cell called B cells
or B lymphocytes. Tafasitamab and obinutuzumab are monoclonal antibodies that may interfere
with the ability of cancer cells to grow and spread. Acalabrutinib is in a class of
medications called kinase inhibitors. It blocks a protein called BTK, which is present on
B-cell cancers such as CLL at abnormal levels. This may help keep cancer cells from growing
and spreading. Giving tafasitamab, acalabrutinib, and obinutuzumab may kill more cancer cells
in patients with previously untreated CLL.
Phase:
Phase 1
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
Incyte Corporation Oregon Health and Science University